Targeting-Acetyl-GD2 Ganglioside for Cancer Immunotherapy

Abstract : Target selection is a key feature in cancer immunotherapy, a promising field in cancer research. In this respect, gangliosides, a broad family of structurally related glycolipids, were suggested as potential targets for cancer immunotherapy based on their higher abundance in tumors when compared with the matched normal tissues. GD2 is the first ganglioside proven to be an effective target antigen for cancer immunotherapy with the regulatory approval of dinutuximab, a chimeric anti-GD2 therapeutic antibody. Although the therapeutic efficacy of anti-GD2 monoclonal antibodies is well documented, neuropathic pain may limit its application. O-Acetyl-GD2, the O-acetylated-derivative of GD2, has recently received attention as novel antigen to target GD2-positive cancers. The present paper examines the role of O-acetyl-GD2 in tumor biology as well as the available preclinical data of anti-O-acetyl-GD2 monoclonal antibodies. A discussion on the relevance of O-acetyl-GD2 in chimeric antigen receptor T cell therapy development is also included.
Type de document :
Article dans une revue
Journal of Immunology Research, Hindawi Publishing Corporation, 2017, 2017, [Epub ahead of print]. 〈10.1182/blood-2013-11-541235〉
Liste complète des métadonnées

Littérature citée [144 références]  Voir  Masquer  Télécharger
Contributeur : Elizabeth Bernardo <>
Soumis le : mercredi 22 février 2017 - 16:34:24
Dernière modification le : jeudi 15 mars 2018 - 14:10:55
Document(s) archivé(s) le : mardi 23 mai 2017 - 14:31:33


Publication financée par une institution




Julien Fleurence, Sophie Fougeray, Meriem Bahri, Denis Cochonneau, Béatrice Clémenceau, et al.. Targeting-Acetyl-GD2 Ganglioside for Cancer Immunotherapy. Journal of Immunology Research, Hindawi Publishing Corporation, 2017, 2017, [Epub ahead of print]. 〈10.1182/blood-2013-11-541235〉. 〈inserm-01474322〉



Consultations de la notice


Téléchargements de fichiers